AUG 14·SEC EDGARLow
Lee Jennifer Kayden sold $8.9M of RYTM
Lee Jennifer Kayden (EVP, Head of North America) sold 75,834 shares of RHYTHM PHARMACEUTICALS, INC. (RYTM) at $117.38 ($8.90M total) on 2026-08-13 under a Rule 10b5-1 trading plan.
StockNASDAQ · US · USDHealthcare · Biotechnology
$RYTM
RHYTHM PHARMACEUTICALS, INC.
Price · $RYTMvia TradingView
AI sentiment · 7d1 articles
- Bullish
- 1
- Neutral
- 0
- Bearish
- 0
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $15.5M 7 txs
Mazabraud Yann6× · $6.6M
10b5-1 share of filings100%
Top stories · $RYTMMore →
AUG 14·SEC EDGAR
Mazabraud Yann sold $6.6M of RYTM
Mazabraud Yann (EVP, Head of International) sold 57,000 shares of RHYTHM PHARMACEUTICALS, INC. (RYTM) at an average of $116.15 ($111.80–$117.47, $6.62M total) across 6 trades on 2026-08-12 under a Rule 10b5-1 trading plan.
AUG 11·fool.com
Rhythm Pharmaceuticals (RYTM) Q2 2026 Earnings Call Transcript
Rhythm Pharmaceuticals (RYTM) reported Q2 2026 revenue of $71.3M, up 19% sequentially. U.S. revenue was $51M, up 38% sequentially, while international sales fell to $20.3M due to a $3.8M French retrospective charge. Management said cash and short-term investments were $330.9M, guiding FY26 non-GAAP OpEx to $363M-$397M and R&D to $175M-$195M.
RYTM sentiment & insider activity
Over the past 7 days, alphai's AI scored 1 news story mentioning RYTM (RHYTHM PHARMACEUTICALS, INC.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent RYTM coverage spans earnings, technology and insider activity.
In the last 30 days, RYTM insiders filed 7 SEC Form 4 transactions — no purchases and 7 sales ($15.5M). The most active reporter was Mazabraud Yann, EVP, Head of International, with 6 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving RYTM
This is a routine 10b5-1 insider sale with no stated operational or financial change, so it is more a positioning signal than a fundamental catalyst.
Insider selling under a 10b5-1 plan is typically not a fundamental negative, but it can modestly affect near-term sentiment and positioning.
Earnings call provides fresh operating and clinical datapoints for RYTM, including updated guidance and RM-718 BMI reduction and hyperpigmentation safety.
The RM-718 Phase 2 readout is a fresh clinical catalyst that can extend the obesity/metabolic rerating narrative, but the article frames the key risk as whether upside is already priced.
Early Phase 2 efficacy and tolerability signals for RM-718 could shift expectations for obesity pipeline value, but the small n and preliminary nature limit conviction.
alphai scores every news story that mentions RYTM with an AI model for sentiment and relevance, and aggregates insider trades from RHYTHM PHARMACEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $RYTM
Score
Lee Jennifer Kayden sold $8.9M of RYTM
Lee Jennifer Kayden (EVP, Head of North America) sold 75,834 shares of RHYTHM PHARMACEUTICALS, INC. (RYTM) at $117.38 ($8.90M total) on 2026-08-13 under a Rule 10b5-1 trading plan.
2 min readMazabraud Yann sold $6.6M of RYTM
Mazabraud Yann (EVP, Head of International) sold 57,000 shares of RHYTHM PHARMACEUTICALS, INC. (RYTM) at an average of $116.15 ($111.80–$117.47, $6.62M total) across 6 trades on 2026-08-12 under a Rule 10b5-1 trading plan.
2 min read
Rhythm Pharmaceuticals (RYTM) Q2 2026 Earnings Call Transcript
Rhythm Pharmaceuticals (RYTM) reported Q2 2026 revenue of $71.3M, up 19% sequentially. U.S. revenue was $51M, up 38% sequentially, while international sales fell to $20.3M due to a $3.8M French retrospective charge. Management said cash and short-term investments were $330.9M, guiding FY26 non-GAAP OpEx to $363M-$397M and R&D to $175M-$195M.
6 min readRhythm Pharmaceuticals (RYTM) Reports Promising RM 718 Data, Is The Upside Already Priced In?
Rhythm Pharmaceuticals (RYTM) released preliminary Phase 2 data for RM-718 in acquired hypothalamic obesity, reporting double-digit mean BMI reductions and generally well-tolerated safety. The stock rose 16.5% over 7 days and 22.79% over 90 days. Simply Wall St cites a $139.47 fair value vs $115.63 close and notes valuation metrics and reliance on setmelanotide (IMCIVREE).
6 min readRhythm Pharmaceuticals reports RM-718 trial results in obesity
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported preliminary Phase 2 results for RM-718, a once-weekly MC4R agonist, in acquired hypothalamic obesity. In 7 patients completing 16 weeks, mean BMI fell 11.6% from baseline. The company cited comparisons versus bivamelagon (10.1% at 14 weeks) and setmelanotide (10.1% at 16 weeks). Mild injection-site hyperpigmentation and common GI side effects were reported.
4 min readRhythm Pharmaceuticals (RYTM) Stock Rises As HO Demand Meets Loss Pressure
Rhythm Pharmaceuticals (RYTM) shares rose 2.9% to $105.78 after a Q2 update. Global net product sales increased to $71.3 million, including early IMCIVREE demand, while the company reported a net loss of $50.4 million. Revenue rose year over year from $48.5 million, but losses widened slightly.
6 min readRhythm Pharmaceuticals Reports Positive Signal For RM-718 In Rare Obesity Disorder
Rhythm Pharmaceuticals (RYTM) reported preliminary Phase 2 results for RM-718, an investigational once-weekly MC4R agonist for acquired hypothalamic obesity. In 11 enrolled patients, 7 reached 16 weeks. Interim data showed mean BMI down 11.6% from baseline, with two mild injection-site hyperpigmentation cases and generally tolerable side effects. Two discontinued; eight remained on treatment as of mid-July 2026.
4 min readRhythm Pharmaceuticals Q2 Earnings Call Highlights
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported Q2 U.S. product revenue of $51M (72% of product sales) and said growth was driven by acquired HO and Bardet-Biedl syndrome demand. International revenue fell to $20.3M due to a France Contribution M charge. GAAP net loss was $0.73/share; cash was ~$331M. RM-718 Phase II Part C showed 11.6% mean BMI reduction at week 16 in 7 patients.
7 min readRhythm Q2 Loss Widens On Higher Expenses, Cuts Outlook For FY26 Operating Expense
Rhythm Pharmaceuticals (RYTM) reported a wider Q2 2026 net loss of $50.36M, or $0.73/share, versus $47.98M, or $0.75/share, as higher operating expenses outweighed 50%+ revenue growth to $71.25M driven by IMCIVREE sales. The company cut FY26 non-GAAP operating expense guidance to $363M-$397M and provided RM-718 and IMCIVREE clinical updates.
4 min readRHYTHM PHARMACEUTICALS, INC. (RYTM): Results of Operations and Financial Condition
RHYTHM PHARMACEUTICALS, INC. (RYTM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026earningspr_draft.htm EX-99.1 Document EXHIBIT 99.1 Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update -- U.S. launch of IMCIVREE ® (setmelanotide) for acquired hypothalamic obesity (HO) starts strong with more than 400 patient
6 min read